Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been assigned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $56.7143.

Several analysts have recently weighed in on IMCR shares. Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th. Zacks Research upgraded shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Jefferies Financial Group lowered Immunocore from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $48.00 to $33.00 in a report on Monday, March 16th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Harbour Investments Inc. lifted its stake in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after purchasing an additional 572 shares during the last quarter. R Squared Ltd increased its stake in Immunocore by 7.4% in the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after purchasing an additional 606 shares during the period. Leonteq Securities AG acquired a new position in Immunocore in the fourth quarter valued at $30,000. Finally, Orion Porfolio Solutions LLC increased its stake in Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after purchasing an additional 1,031 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $33.78 on Thursday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. Immunocore has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The firm has a market capitalization of $1.72 billion, a PE ratio of -61.42 and a beta of 0.73. The stock’s 50-day simple moving average is $29.50 and its 200-day simple moving average is $31.39.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.51. The firm had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 earnings per share. As a group, equities research analysts forecast that Immunocore will post 0.06 EPS for the current fiscal year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.